Neurogene (NGNE) Other Working Capital Changes (2020 - 2026)
Neurogene's (NGNE) quarterly Other Working Capital Changes came in at $45000.0 in Q1 2026, down 83.81% YoY from $278000.0 in Q1 2025, and up 104.33% on a QoQ basis from -$1.0 million in Q4 2025.
Neurogene (NGNE) Other Working Capital Changes (2020 - 2026) Analysis & Trends
Neurogene (NGNE) has 11 years of Other Working Capital Changes data on file, last reported at $45000.0 in Q1 2026.
- Quarterly Other Working Capital Changes fell 83.81% year-over-year to $45000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 million (down 27.69% YoY) and the FY2025 annual result came in at -$952000.0, down 551.18% from the prior year.
- Other Working Capital Changes retreated to -$755000.0 in Q1 2026, from -$740000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $249000.0 in Q4 2022 to a low of -$755000.0 in Q1 2026.
- A 5-year average of -$60117.6 and a median of -$33000.0 in 2025 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2023 — Other Working Capital Changes surged 194.4% — and 2024, when it tumbled 850.0%.
- Tracing NGNE's Other Working Capital Changes over 5 years: stood at $249000.0 in 2022, then plunged by 171.08% to -$177000.0 in 2023, then plunged by 283.05% to -$678000.0 in 2024, then dropped by 9.14% to -$740000.0 in 2025, then slipped by 2.03% to -$755000.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$755000.0 (Q1 2026), -$740000.0 (Q4 2025), and -$745000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -780,000.00 |
| Jun 30, 2026 | -780,000.00 |
| Jun 30, 2026 | -780,000.00 |
| Mar 31, 2026 | -755,000.00 |
| Mar 31, 2026 | -755,000.00 |
| Mar 31, 2026 | -755,000.00 |
| Dec 31, 2025 | -740,000.00 |
| Dec 31, 2025 | -740,000.00 |
| Dec 31, 2025 | -740,000.00 |
| Sep 30, 2025 | -745,000.00 |
| Sep 30, 2025 | -745,000.00 |
| Sep 30, 2025 | -745,000.00 |
| Jun 30, 2025 | -727,000.00 |
| Jun 30, 2025 | -727,000.00 |
| Jun 30, 2025 | -727,000.00 |
| Mar 31, 2025 | -706,000.00 |
| Mar 31, 2025 | -706,000.00 |
| Mar 31, 2025 | -706,000.00 |
| Dec 31, 2024 | -678,000.00 |
| Dec 31, 2024 | -678,000.00 |